Nordic Life Sciences A/S: Financial statements 2022
CVR: 41727659
Source: annual report 2022, Danish Business Authority
01/07/2021 – 30/06/2022
Nordic Life Sciences A/S (CVR 41727659) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -2,426,844 and a net result of DKK -5,004,428. Equity in the 2022 report amounted to DKK -6,014,449.
- Gross Profit
- DKK -2,426,844
- Profit/Loss
- DKK -5,004,428
- Equity
- DKK -6,014,449
- Total Assets
- DKK 3,321,146
Official annual report
Keep an eye on Nordic Life Sciences A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of September 13, 2022, Anders Raft is registered as director of Nordic Life Sciences A/S.
As of September 13, 2022, Pål Anders Nordvi is registered as adm. dir. of Nordic Life Sciences A/S.
As of September 12, 2022, Pål Anders Nordvi has stepped down as director of Nordic Life Sciences A/S.
Nordic Life Sciences A/S has published its interim report for the period September 24, 2020 to June 30, 2021.
About Nordic Life Sciences A/S
Nordic Life Sciences A/S is a Danish company of the type Aktieselskab based in Søndersø, founded in 2020. The company is registered under the industry Fremstilling af farmaceutiske råvarer. The company was previously named Real Canna Denmark A/S and Real Canna Denmark ApS. The management consists of Erik Sundt. The board consists of Erik Sundt and Pål Anders Nordvi. The company is owned by Erik Sundt. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK -8,872,790 and a net result of DKK -9,299,716 compared with DKK -11,050,310 the year before. Equity in the 2025 report amounted to DKK -13,918,223.